Prognostic factors for favorable outcome in disseminated germ cell tumors

R. Birch, S. Williams, A. Cone, Lawrence Einhorn, P. Roark, S. Turner, F. A. Greco

Research output: Contribution to journalArticle

229 Citations (Scopus)

Abstract

Between 1978 and 1982, 180 patients from Indiana University (Indianapolis) were entered on the Southeastern Cancer Study Group (SECSG) protocol 78 GU 240, a randomized comparison of cisplatin, vinblastine, and bleomycin (PVB) v PVB plus doxorubicin induction chemotherapy regimens, with a second randomization to maintenance vinblastine v no further therapy. One hundred forty-eight of these patients obtained a favorable response to chemotherapy, defined as a complete response (CR) or a surgical resection of teratoma. The prognostic significance of various patient characteristics was investigated using the logistic regression model. Two classifications for the extent of disease were considered: the Indiana staging system and the M.D. Anderson (MDA) staging system. The Indiana staging system had the greater prognostic significance. This staging system allowed the population to be split into three groups (minimal, moderate, advanced disease) in which the observed proportions of favorable responders were 99%, 90%, and 58%, respectively. Within the advanced group, the number of elevated tumor markers subdivided these patients into three groups, with the observed proportions of favorable responders being 73%, 65%, and 45%. The Indiana and MDA staging systems were subsequently prospectively used in SECSG protocol GU 81 332, a study randomizing patients to remission induction therapy with PVB v cisplatin, VP-16, and bleomycin. The prognostic value of the Indiana staging system was prospectively validated in this study.

Original languageEnglish (US)
Pages (from-to)400-407
Number of pages8
JournalJournal of Clinical Oncology
Volume4
Issue number3
StatePublished - 1986
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Vinblastine
Bleomycin
Cisplatin
Logistic Models
Remission Induction
Induction Chemotherapy
Teratoma
Etoposide
Tumor Biomarkers
Random Allocation
Doxorubicin
Neoplasms
Maintenance
Drug Therapy
Therapeutics
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Birch, R., Williams, S., Cone, A., Einhorn, L., Roark, P., Turner, S., & Greco, F. A. (1986). Prognostic factors for favorable outcome in disseminated germ cell tumors. Journal of Clinical Oncology, 4(3), 400-407.

Prognostic factors for favorable outcome in disseminated germ cell tumors. / Birch, R.; Williams, S.; Cone, A.; Einhorn, Lawrence; Roark, P.; Turner, S.; Greco, F. A.

In: Journal of Clinical Oncology, Vol. 4, No. 3, 1986, p. 400-407.

Research output: Contribution to journalArticle

Birch, R, Williams, S, Cone, A, Einhorn, L, Roark, P, Turner, S & Greco, FA 1986, 'Prognostic factors for favorable outcome in disseminated germ cell tumors', Journal of Clinical Oncology, vol. 4, no. 3, pp. 400-407.
Birch R, Williams S, Cone A, Einhorn L, Roark P, Turner S et al. Prognostic factors for favorable outcome in disseminated germ cell tumors. Journal of Clinical Oncology. 1986;4(3):400-407.
Birch, R. ; Williams, S. ; Cone, A. ; Einhorn, Lawrence ; Roark, P. ; Turner, S. ; Greco, F. A. / Prognostic factors for favorable outcome in disseminated germ cell tumors. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 3. pp. 400-407.
@article{90a1335df1a349ff8418188919d99cb9,
title = "Prognostic factors for favorable outcome in disseminated germ cell tumors",
abstract = "Between 1978 and 1982, 180 patients from Indiana University (Indianapolis) were entered on the Southeastern Cancer Study Group (SECSG) protocol 78 GU 240, a randomized comparison of cisplatin, vinblastine, and bleomycin (PVB) v PVB plus doxorubicin induction chemotherapy regimens, with a second randomization to maintenance vinblastine v no further therapy. One hundred forty-eight of these patients obtained a favorable response to chemotherapy, defined as a complete response (CR) or a surgical resection of teratoma. The prognostic significance of various patient characteristics was investigated using the logistic regression model. Two classifications for the extent of disease were considered: the Indiana staging system and the M.D. Anderson (MDA) staging system. The Indiana staging system had the greater prognostic significance. This staging system allowed the population to be split into three groups (minimal, moderate, advanced disease) in which the observed proportions of favorable responders were 99{\%}, 90{\%}, and 58{\%}, respectively. Within the advanced group, the number of elevated tumor markers subdivided these patients into three groups, with the observed proportions of favorable responders being 73{\%}, 65{\%}, and 45{\%}. The Indiana and MDA staging systems were subsequently prospectively used in SECSG protocol GU 81 332, a study randomizing patients to remission induction therapy with PVB v cisplatin, VP-16, and bleomycin. The prognostic value of the Indiana staging system was prospectively validated in this study.",
author = "R. Birch and S. Williams and A. Cone and Lawrence Einhorn and P. Roark and S. Turner and Greco, {F. A.}",
year = "1986",
language = "English (US)",
volume = "4",
pages = "400--407",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "3",

}

TY - JOUR

T1 - Prognostic factors for favorable outcome in disseminated germ cell tumors

AU - Birch, R.

AU - Williams, S.

AU - Cone, A.

AU - Einhorn, Lawrence

AU - Roark, P.

AU - Turner, S.

AU - Greco, F. A.

PY - 1986

Y1 - 1986

N2 - Between 1978 and 1982, 180 patients from Indiana University (Indianapolis) were entered on the Southeastern Cancer Study Group (SECSG) protocol 78 GU 240, a randomized comparison of cisplatin, vinblastine, and bleomycin (PVB) v PVB plus doxorubicin induction chemotherapy regimens, with a second randomization to maintenance vinblastine v no further therapy. One hundred forty-eight of these patients obtained a favorable response to chemotherapy, defined as a complete response (CR) or a surgical resection of teratoma. The prognostic significance of various patient characteristics was investigated using the logistic regression model. Two classifications for the extent of disease were considered: the Indiana staging system and the M.D. Anderson (MDA) staging system. The Indiana staging system had the greater prognostic significance. This staging system allowed the population to be split into three groups (minimal, moderate, advanced disease) in which the observed proportions of favorable responders were 99%, 90%, and 58%, respectively. Within the advanced group, the number of elevated tumor markers subdivided these patients into three groups, with the observed proportions of favorable responders being 73%, 65%, and 45%. The Indiana and MDA staging systems were subsequently prospectively used in SECSG protocol GU 81 332, a study randomizing patients to remission induction therapy with PVB v cisplatin, VP-16, and bleomycin. The prognostic value of the Indiana staging system was prospectively validated in this study.

AB - Between 1978 and 1982, 180 patients from Indiana University (Indianapolis) were entered on the Southeastern Cancer Study Group (SECSG) protocol 78 GU 240, a randomized comparison of cisplatin, vinblastine, and bleomycin (PVB) v PVB plus doxorubicin induction chemotherapy regimens, with a second randomization to maintenance vinblastine v no further therapy. One hundred forty-eight of these patients obtained a favorable response to chemotherapy, defined as a complete response (CR) or a surgical resection of teratoma. The prognostic significance of various patient characteristics was investigated using the logistic regression model. Two classifications for the extent of disease were considered: the Indiana staging system and the M.D. Anderson (MDA) staging system. The Indiana staging system had the greater prognostic significance. This staging system allowed the population to be split into three groups (minimal, moderate, advanced disease) in which the observed proportions of favorable responders were 99%, 90%, and 58%, respectively. Within the advanced group, the number of elevated tumor markers subdivided these patients into three groups, with the observed proportions of favorable responders being 73%, 65%, and 45%. The Indiana and MDA staging systems were subsequently prospectively used in SECSG protocol GU 81 332, a study randomizing patients to remission induction therapy with PVB v cisplatin, VP-16, and bleomycin. The prognostic value of the Indiana staging system was prospectively validated in this study.

UR - http://www.scopus.com/inward/record.url?scp=0022576065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022576065&partnerID=8YFLogxK

M3 - Article

C2 - 2419524

AN - SCOPUS:0022576065

VL - 4

SP - 400

EP - 407

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 3

ER -